From a single vial of maternal blood drawn as early as 10 weeks into pregnancy, researchers at the Broad Institute of MIT and Harvard have developed a test that can screen nearly 23,000 genes—revealing genetic conditions that currently require risky, invasive procedures. The technique, called noninvasive fetal sequencing (NIFS), represents a quiet revolution in prenatal diagnostics, one that could spare tens of thousands of pregnant women from the anxiety and procedural risks that accompany the current gold standard of testing.
For decades, pregnant women have faced a difficult choice: accept limited genetic information from noninvasive blood tests, or undergo amniocentesis or chorionic villus sampling—procedures that carry a small but real risk of miscarriage. Most current noninvasive prenatal testing (NIPT) methods are low-resolution, screening only a handful of genetic abnormalities with limited standardization. Comprehensive genetic testing has remained the exclusive domain of these invasive procedures, leaving many genetic causes of fetal abnormalities undetected. Women have refused invasive testing in large numbers, Dr. Christopher Whelan, a senior computational scientist at the Broad Institute and Massachusetts General Hospital, explains, "because of the risk to the fetus, related stress, difficulties of access and cost, even though their diagnostic capacity is high."
Whelan's team set out to close this gap. They tested NIFS on 565 pregnancies at an average of 17 weeks of gestation, using deep cell-free fetal DNA sequencing on maternal blood samples and advanced computing to identify genetic variants across the fetal exome. When they checked their results against direct sequencing from amniocentesis or chorionic villus sampling—the current invasive standard—the findings were striking. NIFS detected 95 to 99 percent of the genetic variants found by invasive methods, depending on the type of variant and inheritance pattern. Most critically, the test identified 97.2 percent of genetic variants responsible for clinically important conditions.
The accuracy was so robust that it revealed unexpected discoveries along the way. The researchers detected twin pregnancies with abnormal tissue, and uncovered evidence that some mothers had received bone marrow transplants from male donors—findings that had confounded previous noninvasive test results. These unexpected detections only strengthened confidence in the technique's precision.
Beyond accuracy, NIFS offers tangible advantages that extend far beyond the medical. Because it uses capabilities that already exist in commercial diagnostic laboratories and requires no medical procedure, it is estimated to cost considerably less than invasive genome sequencing. The test can be performed as early as 10 weeks of gestation, giving parents genetic information long before most fetal abnormalities become visible on imaging. Even when the fetal fraction—the proportion of cell-free DNA in maternal blood that comes from the placenta—dipped as low as 3 percent, the test maintained very high concordance with clinical sequencing from invasive testing.
For pregnant women and their families, NIFS offers something profound: earlier answers without the procedural risks. By providing genetic diagnoses earlier in pregnancy, the test allows for more informed decision-making and can ultimately reduce overall healthcare costs through better-guided management. Dr. Whelan and his team are now working to expand NIFS further, identifying additional clinically relevant genetic variants not assessed by standard exome screening. The technique, to be presented at the annual conference of the European Society of Human Genetics, points toward a future where comprehensive prenatal genetic testing is both safe and accessible to all.